Riskpilot← Back to searchSign inGet full accessNxtScience AB
ABActiveOrg 5569611113Business and other management consultancy activities · NACE 7020Est. 20140 employees
Revenue 2025
SEK 0
EBITDA margin
—
0% vs 2024
Equity ratio
95.5%
Financial strength
Net profit 2025
SEK 3,8M
+7024% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -24K | +0% |
| Net profit | SEK 3,8M | +7024% |
| Total assets | SEK 8,6M | +76% |
| Equity | SEK 8,2M | +73% |
| Employees | 0 | — |
Legal name
NxtScience AB
Org number
5569611113
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
6 februari 2014
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget ska ägna sig åt rådgivning och konsultverksamhet inom lifescience (dvs forskning, utveckling och undervisning för sjuk- och hälsovård), samt management och därmed förenlig verksamhet.
Address
Phone
+46705902978
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −30 | −28 | −24 | −24 | −24 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −30 | −28 | −24 | −24 | −24 |
| Net financials | 1 491 | −261 | 35 | 56 | 3 851 |
| Profit before tax | 1 462 | −169 | 502 | 68 | 3 827 |
| Tax | −0 | — | −111 | −15 | — |
| Net profit | 1 462 | −169 | 391 | 54 | 3 827 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 5 910 | 5 626 | 5 636 | 4 890 | 8 606 |
| Equity | 5 253 | 5 084 | 5 474 | 4 739 | 8 217 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 10 | 15 | 126 | 151 | 390 |
| Total debt | 10 | 15 | 126 | 151 | 390 |
EBITDA margin
-2411200.0%
This company
15.8%
Market median
-15260859% vs market
20212025
Equity ratio
95.5%
This company
38.2%
Market median
+150% vs market
20212025
Return on equity
46.6%
This company
18.4%
Market median
+153% vs market
20212025
Net profit margin
382731300.0%
This company
8.1%
Market median
+4725077678% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NxtScience AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Olof Adolf Ekblom | Board of Directors | 0 companies |
| Lena Kristina Ekblom | Deputy Board Member | 0 companies |